Browse Articles
Discover research articles across all indexed journals
Molecular mechanisms of mitochondrial Ca2+ exchanger NCLX
Abstract Mitochondrial Ca²⁺ homeostasis is maintained through coordinated influx and efflux processes, with NCLX long recognized as the primary Ca²⁺ extruder operating via Na⁺/Ca²⁺ exchange. Here, we report cryo-EM structures of rat NCLX in cytosolic-facing occluded and open states. The central transmembrane (TM) domain of NCLX comprises ten helices arranged in two inverted, structurally similar halves, with two α-repeats forming a central ion-binding pocket. Peripheral TMs 1 and 6 are loosely associated with the core and likely mediate alternative access to this site. These structural features closely resemble those of NCXs, indicating a conserved ion exchange mechanism. While NCLX retains the canonical Ca²⁺-binding site, it lacks several key Na⁺-binding residues found in NCXs, suggesting broader ion selectivity. Consistently, cell-based Ca²⁺ uptake assays show that NCLX mediates Ca²⁺ exchange using Na⁺, K⁺, Li⁺, and potentially protons as counterions. Based on the structural symmetry of NCLX and its bidirectional exchange capability, we propose a matrix-facing model and an alternating-access mechanism in which TMs 1 and 6 undergo sliding motions to enable ion exchange between cytosolic and matrix sides, analogous to NCX. These findings provide a structural and mechanistic framework for understanding NCLX-mediated Ca²⁺ transport in mitochondria.
Effect of probiotic Bacillus cereus PKA18 on the overall growth, gut microbiome, and immunity in Clarias magur (Hamilton, 1822)
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
A paired electrolysis for hydroxymethanesulfonate synthesis using sulfide waste as the sulfur source
An edge-AI framework with graph transformer learning for resilient microgrid topology attack identification
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation
Cancer treatment is evolving from organ-based classification toward biomarker-driven precision medicine, culminating in the development of tumor-agnostic therapies approved based on molecular characteristics, irrespective of tumor origin. Since the US Food and Drug Administration's landmark 2017 approval of pembrolizumab for microsatellite instability-high tumors, nine tumor-agnostic drugs have been approved, offering unprecedented treatment options for patients with rare cancers and actionable genomic alterations. However, this scientific breakthrough has revealed profound global implementation challenges. We reviewed the current landscape of tumor-agnostic drug approvals, regulatory pathways, and implementation experiences across multiple regions, including Europe, Asia-Pacific, Latin America, Africa, and the Middle East. Barriers to access were examined across regulatory, reimbursement, infrastructure, and workforce domains to inform a conceptual framework for implementation. Access remains inconsistent even in high-resource settings, with fewer than 50% of eligible patients receiving matched therapies. In Europe, centralized regulatory approval through the European Medicines Agency contrasts sharply with fragmented national reimbursement decisions, creating delays in access. Asia-Pacific nations demonstrate rapid growth in tumor-agnostic approvals and drug development capacity, although significant urban-rural disparities persist. Latin America, Africa, and areas in the Middle East face fundamental barriers, including limited testing infrastructure, workforce shortages, and competing health care priorities. To address these challenges, we propose a four-pillar framework for equitable implementation: comprehensive biomarker testing capability, innovative clinical trial designs with decision-support systems, harmonized regulatory approval and reimbursement mechanisms, and investment in genomically competent workforce development. International initiatives including Project Orbis and cross-border trial consortia demonstrate promising models for regulatory convergence. Realizing the transformative potential of tumor-agnostic therapies requires coordinated global strategies that bridge the divide between genomic innovation and geographic accessibility, ensuring all patients benefit regardless of socioeconomic status or location.
Segmental duplications and supernumerary chromosomes drive antifungal drug resistance in Candida auris
Correction: Examining the effects of cigarette smoke on mouse lens through a multi OMIC approach
From Darkness to Light
Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting
Lactiplantibacillus plantarum OP5: a novel strain with antioxidant properties for quality improvement of fermented sausage
Different Stage But Similar Survival in Hepatocellular Carcinoma: A Dilemma of Treatment Timing?
Genetic drivers of etiologic heterogeneity in thyroid cancer
Abstract Thyroid cancer is the most common endocrine malignancy, yet its biological underpinnings remain incompletely understood. Here we show that common risk alleles for thyroid cancer point to distinct biological pathways underlying disease susceptibility. We perform a multi-ancestry genome-wide association meta-analysis of thyroid cancer (16,167 cases and 2,430,374 controls), identifying 51 independent loci, including 21 not previously reported. By integrating these loci with genetic associations for 151 thyroid-cancer-related traits, we identify pleiotropic mechanistic clusters linked to thyroid function, oncogenic pathways, and mixed physiological function. Two thyroid-specific clusters, associated with thyroid stimulating hormone or thyroid growth and function, are enriched in thyroid tissues. Oncogenic clusters include DNA repair ( ATM , CHEK2 , TP53 ) and telomere maintenance ( TERT ) genes, implicating shared cancer mechanisms. Cluster-specific polygenic scores are associated with thyroid disease, cancer, and metabolic traits across ancestry groups, suggesting distinct genetic subtypes of thyroid cancer risk and supporting pleiotropy-based approaches to genetic risk stratification.
Novel approach to early prediction of alzheimer’s disease progression using integrated deep regulatory genetic neural network and optimized deep belief networks
Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743
Exercise-associated microbial metabolites prevent skeletal muscle atrophy in adult female mice
Abstract We previously reported that skeletal muscle adaptation to regular exercise requires a healthy gut microbiome, contributing to growing evidence that some exercise benefits are mediated by microbiome-derived metabolites. Here, to identify such exercise-associated microbial metabolites, we transfer cecal contents from exercise-trained female donor mice into exercise-naïve female recipient mice undergoing unilateral hindlimb immobilization. Recipients of cecal material from exercise-trained donors exhibit less muscle atrophy compared with those receiving transfers from sedentary donors. Untargeted metabolomics reveal metabolites enriched in cecal content, serum, and muscle of recipients from exercise-trained donors, consistent with microbial origin. Oral administration of two such metabolites (pipecolic acid and succinate) attenuates muscle atrophy and preserves muscle function in exercise-naïve mice, potentially by enhancing cellular energy status and translational capacity. These findings further define the gut microbiome-skeletal muscle axis and provide evidence that exercise-associated microbial metabolites serve as a novel class of exercise mimetics for treating conditions responsive to physical activity.
RANSAC guided modeling and evolutionary optimization of UV/sulfite for ofloxacin removal
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
PURPOSE In immunoglobulin light chain (AL) amyloidosis, amyloid fibrils cause organ dysfunction. Anselamimab, a monoclonal antibody, selectively binds to amyloid fibrils, accelerating their clearance. METHODS Newly diagnosed patients with European modification of Mayo 2004 stage IIIa or IIIb AL amyloidosis were randomly assigned to receive anselamimab or placebo with cyclophosphamide, bortezomib, and dexamethasone (with or without daratumumab). The primary end point was a hierarchical composite of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalizations (CVHs), analyzed using the Finkelstein-Schoenfeld test and win ratio estimation. RESULTS Among 406 randomly assigned patients, the primary end point win ratio for anselamimab versus placebo was 1.11 (95% CI, 0.83, 1.50; P = .332) and the hazard ratio (HR) for ACM was 0.80 (95% CI, 0.57, 1.13; P = .290). CVH rates in the anselamimab and placebo groups were 0.59 (95% CI, 0.42, 0.83) and 0.89 (95% CI, 0.55, 1.43), respectively ( P = .145). Among patients with kappa isotype (n = 72), the win ratio was 2.06 (95% CI, 0.98, 4.31; P = .100) and anselamimab reduced ACM by 62% versus placebo (HR, 0.38; 95% CI, 0.17 to 0.86; nominal P = .012), and CVH by 71% (IRR, 0.29; 95% CI, 0.10 to 0.87; nominal P = .028) with improvements in Kansas City Cardiomyopathy Questionnaire-Overall Score. There was no clinical benefit observed in the lambda population. Anselamimab was generally well-tolerated; safety data were comparable between treatment arms overall. CONCLUSION Treatment with anselamimab, an antifibril antibody used alongside antiplasma cell dyscrasia therapy, while not meeting the primary end point in the overall population, significantly improved ACM and CVH in patients with kappa AL, potentially offering a new therapeutic option for this isotype.